Celcuity, Inc. (NASDAQ:CELC) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC) have been given an average recommendation of “Moderate Buy” by the twelve ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and eleven have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $152.0909.

A number of equities analysts recently commented on the stock. Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Wells Fargo & Company decreased their target price on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Wolfe Research reissued an “outperform” rating and issued a $110.00 target price on shares of Celcuity in a report on Thursday, March 12th. Guggenheim reissued a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Finally, Macquarie Infrastructure set a $160.00 target price on shares of Celcuity in a report on Thursday, May 28th.

Celcuity Stock Up 0.3%

CELC stock opened at $90.21 on Wednesday. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The firm has a market capitalization of $4.40 billion, a PE ratio of -23.13 and a beta of 0.10. Celcuity has a 1-year low of $11.27 and a 1-year high of $151.02. The business’s 50 day simple moving average is $115.92 and its 200 day simple moving average is $110.75.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. As a group, research analysts anticipate that Celcuity will post -3.69 EPS for the current year.

Insider Activity

In related news, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. The trade was a 57.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director directly owned 65,000 shares in the company, valued at $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 37,000 shares of company stock worth $5,111,950. Insiders own 13.33% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CELC. Vanguard Group Inc. boosted its holdings in shares of Celcuity by 23.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock worth $101,717,000 after buying an additional 391,262 shares during the last quarter. Choreo LLC purchased a new position in shares of Celcuity in the 3rd quarter worth about $248,000. TD Asset Management Inc purchased a new position in shares of Celcuity in the 3rd quarter worth about $3,596,000. Jennison Associates LLC purchased a new position in shares of Celcuity in the 4th quarter worth about $22,911,000. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Celcuity in the 3rd quarter worth about $1,351,000. 63.33% of the stock is owned by institutional investors.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.